Myelosuppression Risks and Monitoring
Lurbinectedin causes severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Monitor complete blood counts prior to each cycle, weekly for the first two cycles, and as clinically indicated thereafter. Delay or reduce dose if neutrophils drop below 1.5 × 10^9/L or platelets below 100 × 10^9/L. Administer growth factors for secondary prophylaxis if febrile neutropenia occurs or persistent grade 4 neutropenia develops.[1][2]
Hepatotoxicity Precautions
Elevated liver enzymes occur frequently. Assess liver function tests before each cycle. Withhold treatment for grade 3 or 4 elevations and resume at reduced dose once resolved to grade 1 or baseline. Avoid use in patients with active hepatitis or significant baseline liver impairment.[1][2]
Infusion Reactions and Premedication
Infusion-related reactions, including fever and hypersensitivity, can happen during or after administration. Premedicate with corticosteroids (e.g., dexamethasone 10 mg IV), antihistamines (e.g., dexchlorpheniramine 5 mg IV or equivalent), and antiemetics 30-60 minutes prior. Monitor closely during the 60-minute IV infusion; slow or interrupt if reactions occur, and permanently discontinue for severe cases.[1][2]
Extravasation Prevention
Lurbinectedin is a vesicant. Administer via central venous catheter if possible; if peripheral, use good vein selection and monitor site. If extravasation suspected, stop infusion immediately, aspirate residual drug, and apply cold compresses. Elevate limb and consult guidelines for vesicant management.[1][2]
Drug Interactions to Avoid
Lurbinectedin is metabolized by CYP3A4; avoid strong CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), which alter exposure. Hold inhibitors 3-5 half-lives prior and resume after 3-5 half-lives post-dose. No routine monitoring needed for moderate inhibitors, but watch for toxicity.[1][2]
Renal and Special Population Adjustments
No dose adjustment for mild-moderate renal impairment (CrCl ≥30 mL/min); data limited for severe cases—use caution. No adjustments for mild hepatic impairment (bilirubin ≤ULN, AST >ULN); avoid in moderate-severe. Not studied in pediatrics or pregnancy (contraindicated; use effective contraception).[1][2]
General Administration Guidelines
Dilute in 500 mL 0.9% NaCl or D5W, infuse over 60 minutes every 21 days. Store refrigerated; use within 24 hours at room temp. Compatible with PVC/PE/PP bags and administration sets.[1][2]
Sources
[1]: Zepzelca (lurbinectedin) Prescribing Information
[2]: Drugs.com - Lurbinectedin Precautions